Sertraline: A review of its use in the management of major depressive disorder in elderly patients

Drugs and Aging

Volumn 19, Issue 5, 2002, Pages 377-392

  Muijsers, Richard B R ^a   Plosker, Greg L ^a   Noble, Stuart ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DIGOXIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

AGED; ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG UPTAKE; HEADACHE; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; SIDE EFFECT; XEROSTOMIA;

EID: 0036076961     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219050-00006     Document Type: Review

References (68)

1. Selective serotonin reuptake inhibitors for late-life depression: A comparative review
2. Use of antidepressants by nonpsychiatrists in the treatment of medically ill hospitalized depressed elderly patients
3. Depression in the elderly. How to recognize masked symptoms and choose appropriate therapy
4. The use of selective serotonin reuptake inhibitors in geriatric depression: A review of the literature
5. Managing depression in medical out-patients
6. Clinical comparison of selective serotonin reuptake inhibitors in the treatment of geriatric depression: A review of literature
7. Primary care issues related to the treatment of depression in elderly patients
8. Diagnosis and treatment of depression in late life: The NIH Consensus Development Conference Statement
9. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive compulsive disorder
10. The selective serotonin reuptake inhibitor sertraline: Its profile and use in psychiatric disorders
11. Sertraline: An overview of its pharmacological properties and a review of its therapeutic efficacy in obsessive-compulsive disorder
12. Pharmacological characterization of the cloned human 5- hydroxytryptamine transporter
13. Pharmacological profile of antidepressants and related compounds at human monoamine transporters
14. Differential pharmacology of newer antidepressants
15. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders
16. Cognitive and psychomotor effects of antidepressants with emphasis on selective serotonin reuptake inhibitors and the depressed elderly patient
17. Brain serotonin and the mechanism of action of selective serotonin re-uptake inhibitors (SSRI)
18. The serotonin transporter: A primary target for antidepressant drugs
19. Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine
20. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life
21. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients
22. The effects of sertraline on psychomotor performance in elderly volunteers
23. Acute effects of sertraline, amitriptyline, and placebo on the psychomotor performance of healthy subjects over 50 years of age
24. Care of depression in the elderly: Comparative pharmacokinetics of SSRIs
25. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers
26. Sertraline: Chronopharmacokinetics and the effect of coadministration with food
27. Pharmacokinetics of selective serotonin reuptake inhibitors: Clinical relevance
28. Clinical implications of the pharmacology of sertraline
29. Clinical pharmacokinetics of selective serotonin reuptake inhibitors
30. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N- demethylation of sertraline in human liver microsomes
31. Influence of liver cirrhosis on sertraline pharmacokinetics
32. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism
33. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients
34. Antidepressant efficacy and safety of low-dose sertraline and standard- dose imipramine for the treatment of depression in older adults: Results from a double-blind, randomized, controlled clinical trial
35. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: Initial results from the Depression in Alzheimer's Disease study
36. Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression
37. Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 and older
38. Late-life depression and medical comorbidity: Implications for treatment response
39. Therapeutic response to sertraline in medically depressed elderly
40. Severe hyponatraemia associated with selective serotonin reuptake inhibitors
41. Hyponatraemia and selective serotonin reuptake inhibitors in elderly patients
42. Sertraline-associated syndrome of inappropriate antidiuretic hormone: Case report and review of the literature
43. SSRI safety in overdose
44. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance
45. Practice guidelines for the treatment of patients with major depressive disorder (revision)
46. Diagnosing and treating depression in the elderly
47. Selective serotonin reuptake inhibitors in older patients: A tolerability perspective
48. Use of serotonin selective reuptake inhibitors in geriatric depression
49. Practical considerations for the treatment of depression in elderly and very elderly long-term care patients
50. Pharmacological and psychological treatments for depressed older patients: A meta-analysis and overview of recent findings
51. Meta-analytical studies on new antidepressants
52. Selective serotonin-reuptake inhibitors: An update
53. Diagnosis and treatment of depression in late life: Consensus statement update
54. Rational antidepressant selection in the elderly
55. Selective serotonin reuptake inhibitors in affective disorders-I. Basic pharmacology
56. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence
57. Systematic review and guide to selection of selective serotonin reuptake inhibitors
58. Pharmacotherapy of affective disorders in old age
59. Antidepressant drug interactions in the elderly: Understanding the P-450 system is half the battle in reducing risks